The Indiana Biosciences Research Institute (IBRI) is an American nonprofit translational research organization headquartered in Indianapolis, Indiana, United States[1] within the 16 Tech Innovation District.[2] The IBRI is the nation's first industry-led collaborative life sciences research institute.[3] Its primary focus is on better understanding the pathogenesis of type 1 and type 2 diabetes to translate this knowledge into novel therapies,[4] while also expanding into other metabolic diseases that share common systems and pathways.[5]
Formation | May 1, 2013 |
---|---|
Type | Research Institute |
Headquarters | Indianapolis, Indiana, U.S. |
Region served | Indiana |
Staff | 100 |
Website | http://indianabiosciences.org |
In 2012, pharmaceutical executive John C. Lechleiter from Eli Lilly & Company initially proposed the IBRI.[6][7] In 2013, Indiana governor Mike Pence announced the formation of the IBRI.[8] Pence later worked with life sciences leaders to secure $25 million in startup funds from the state.[9]
In 2015, the IBRI hired David Broecker as CEO.[10] In late 2015, the Indianapolis City-County Council approved $75 million to build a technology park called 16 Tech.[11] In 2016, the IBRI hired Rainer Fischer as Chief Scientific Officer.[12][13] In 2017, Governor Eric Holcomb reaffirmed the commitment made by his predecessor Mike Pence.[14][15][16]
Appointees to the IBRI’s Board of Directors include: